← 返回

间充质干细胞来源外泌体启发的纳米制剂:靶向癌症治疗的新前沿

英文原题:Mesenchymal stem cell-derived exosome-inspired nanoformulations: a new frontier in targeted cancer therapy.

查看英文原题

Mesenchymal stem cell-derived exosome-inspired nanoformulations: a new frontier in targeted cancer therapy.

PubMed 2026/05/02(内容时间) Int J Pharm Q1 · IF 6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

间充质干细胞(MSC)来源的外泌体启发纳米制剂近年来被提出作为一种新兴的靶向癌症治疗方法,克服了传统癌症治疗的局限性,如肿瘤选择性低、全身毒性以及耐药性的产生。外泌体,尤其是MSC来源的外泌体,已知可提供一种高效且生物相容的方式,将包括化疗药物在内的多种治疗药物靶向递送至肿瘤部位。

在此,我们对MSC来源外泌体(MSCEs)启发纳米制剂的独特方面进行了综合性综述,包括其肿瘤靶向策略,如趋化性、受体介导的摄取、免疫逃逸和细胞内递送,以及它们在癌细胞信号传导中的意义。

此外,还对外泌体生物工程化构建方法的最新进展以及外泌体模拟纳米载体的应用进行了批判性评估。除了涵盖化疗、基于RNA的治疗、免疫调节和联合方案的治疗应用外,我们还对与大规模生产、标准化和监管转化相关的优势、局限性和关键挑战进行了平衡讨论。

总体而言,本综述提供了一个连接生物学机制与纳米技术工程的统一框架,将MSCEs启发纳米制剂定位为精准肿瘤学的下一代平台。

展开英文摘要原文

Mesenchymal stem cell (MSC)-derived exosome-inspired nanoformulations have recently been proposed as an emerging approach for targeted cancer therapies, which overcome the limitations of conventional cancer therapies, such as low tumor selectivity, systemic toxicity, and the development of drug resistance. Exosomes, particularly MSC-derived exosomes, are known to offer an efficient and biocompatible approach for the targeted delivery of various therapeutic agents, including chemotherapeutic agents, to the tumor site.

Here, we provide an integrative review on the unique aspects of MSC-derived exosomes (MSCEs)-inspired nanoformulations, including their tumor-targeting strategies, such as chemotaxis, receptor-mediated uptake, immune escape, and intracellular delivery, as well as their implications in cancer cell signaling.

Further, the recent developments in the fabrication of bioengineering approaches for exosomes and the application of exosome-mimetic nanocarriers are also critically evaluated.

In addition to therapeutic applications encompassing chemotherapy, RNA-based therapies, immunomodulation, and combination approaches, we provide a balanced discussion of the advantages, limitations, and key challenges related to large-scale production, standardization, and regulatory translation. Collectively, this review offers a unified framework bridging biological mechanisms and nanotechnological engineering, positioning MSCEs-inspired nanoformulations as next-generation platforms for precision oncology.

论文信息

作者
Jadhav RS、Koparde A、Kadam AB、Kanaujia KA
单位
Department of Pharmaceutical Chemistry, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad-415539, India. Electronic address: ranjitjadhav705@gmail.com.India
文献类型
综述
期刊
International journal of pharmaceutics2026 Jun 5
原文标识
PubMed 42082061 · DOI 10.1016/j.ijpharm.2026.126929